PURPOSE: This retrospective cohort study aimed to determine the predictive relevance of clinical characteristics, additional cytogenetic aberrations, and cKIT and RAS mutations, as well as to evaluate whether specific treatment elements were associated with outcomes in pediatric t(8;21)-positive patients with acute myeloid leukemia (AML). PATIENTS AND METHODS: Karyotypes of 916 pediatric patients with t(8;21)-AML were reviewed for the presence of additional cytogenetic aberrations, and 228 samples were screened for presence of cKIT and RAS mutations. Multivariable regression models were used to assess the relevance of anthracyclines, cytarabine, and etoposide during induction and overall treatment. End points were the probability of achieving complete remission, cumulative incidence of relapse (CIR), probability of event-free survival, and probability of overall survival. RESULTS: Of 838 patients included in final analyses, 92% achieved complete remission. The 5-year overall survival, event-free survival, and CIR were 74%, 58%, and 26%, respectively. cKIT mutations and RAS mutations were not significantly associated with outcome. Patients with deletions of chromosome arm 9q [del(9q); n = 104] had a lower probability of complete remission (P = .01). Gain of chromosome 4 (+4; n = 21) was associated with inferior CIR and survival (P < .01). Anthracycline doses greater than 150 mg/m(2) and etoposide doses greater than 500 mg/m(2) in the first induction course and high-dose cytarabine 3 g/m(2) during induction were associated with better outcomes on various end points. Cumulative doses of cytarabine greater than 30 g/m(2) and etoposide greater than 1,500 mg/m(2) were associated with lower CIR rates and better probability of event-free survival. CONCLUSION: Pediatric patients with t(8;21)-AML and additional del(9q) or additional +4 might not be considered at good risk. Patients with t(8;21)-AML likely benefit from protocols that have high doses of anthracyclines, etoposide, and cytarabine during induction, as well as from protocols comprising cumulative high doses of cytarabine and etoposide.

Kim Klein Gertjan Kaspers Jacqueline Cloos and Mathilda Bongers Vrije Universiteit University Medical Center Amsterdam; Gertjan Kaspers and Ardine Reedijk Dutch Childhood Oncology Group The Hague; H Berna Beverloo Erasmus Medical Center Rotterdam the Netherlands; Christine J Harrison Newcastle University Newcastle upon Tyne; Brenda Gibson Royal Hospital for Sick Children Glasgow United Kingdom; Andrea Pession Italian Association of Pediatric Hematology Oncology Bologna Italy; Dirk Reinhardt Berlin Frankfurt Münster PA; Michal Zapotocky Czech Paediatric Hematology Working Group Prague Czech Republic; Barbara De Moerloose European Organisation for Research and Treatment of Cancer Children's Leukemia Group Brussels Belgium; Alcira Flynn Grupo Argentino de Tratamiento de la Leucemia Aguda Buenos Aires Argentina; Vincent Lee Hong Kong Paediatric Haematology and Oncology Study Group Hong Kong Special Administrative Region People's Republic of China; Takashi Taga Japanese Pediatric Leukemia Lymphoma Study Group Otsu; Akio Tawa Japanese Pediatric Leukemia Lymphoma Study Group Osaka Japan; Anne Auvrignon French Leucémie Aiguë Myéloblastique Enfant Cooperative Group Paris France; Bernward Zeller Nordic Society of Paediatric Haematology and Oncology Oslo Norway; Erik Forestier Nordic Society of Paediatric Haematology and Oncology Umeå Sweden; Carmen Salgado The National Program for Antineoplastic Drugs for Children Santiago Chile; Walentyna Balwierz Polish Pediatric Leukemia Lymphoma Study Group Krakow Poland; Alexander Popa Russian Acute Myeloid Leukemia Study Group Moscow Russia; and Jeffrey Rubnitz and

J Clin Oncol. 2015 Dec 20;33(36):4238-9. doi: 10.1200/JCO.2015.63.9252. PubMed

Zobrazit více v PubMed

Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial—The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998;92:2322–2333. PubMed

Marcucci G, Mrozek K, Ruppert AS, et al. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): A Cancer and Leukemia Group B study. J Clin Oncol. 2005;23:5705–5717. PubMed

Creutzig U, Zimmermann M, Bourquin JP, et al. Second induction with high-dose cytarabine and mitoxantrone: Different impact on pediatric AML patients with t(8;21) and with inv(16) Blood. 2011;118:5409–5415. PubMed

von Neuhoff C, Reinhardt D, Sander A, et al. Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98. J Clin Oncol. 2010;28:2682–2689. PubMed

Martinez-Climent JA, Lane NJ, Rubin CM, et al. Clinical and prognostic significance of chromosomal abnormalities in childhood acute myeloid leukemia de novo. Leukemia. 1995;9:95–101. PubMed

Pession A, Masetti R, Rizzari C, et al. Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia. Blood. 2013;122:170–178. PubMed

Chang M, Raimondi SC, Ravindranath Y, et al. Prognostic factors in children and adolescents with acute myeloid leukemia (excluding children with Down syndrome and acute promyelocytic leukemia): Univariate and recursive partitioning analysis of patients treated on Pediatric Oncology Group (POG) Study 8821. Leukemia. 2000;14:1201–1207. PubMed

Nguyen S, Leblanc T, Fenaux P, et al. A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): A survey of 161 cases from the French AML Intergroup. Blood. 2002;99:3517–3523. PubMed

Jung HA, Maeng CH, Park S, et al. Prognostic factor analysis in core-binding factor-positive acute myeloid leukemia. Anticancer Res. 2014;34:1037–1045. PubMed

Rege K, Swansbury GJ, Atra AA, et al. Disease features in acute myeloid leukemia with t(8;21)(q22;q22): Influence of age, secondary karyotype abnormalities, CD19 status, and extramedullary leukemia on survival. Leuk Lymphoma. 2000;40:67–77. PubMed

Rubnitz JE, Raimondi SC, Halbert AR, et al. Characteristics and outcome of t(8;21)-positive childhood acute myeloid leukemia: A single institution's experience. Leukemia. 2002;16:2072–2077. PubMed

Raimondi SC, Chang MN, Ravindranath Y, et al. Chromosomal abnormalities in 478 children with acute myeloid leukemia: Clinical characteristics and treatment outcome in a cooperative pediatric oncology group study-POG 8821. Blood. 1999;94:3707–3716. PubMed

Creutzig U, Zimmermann M, Bourquin JP, et al. Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: Results from study AML-BFM 2004. Blood. 2013;122:37–43. PubMed

Willatt L, Morgan S, Shaffer LG, et al. ISCN 2009 an international system for human cytogenetic nomenclature. Hum Genet. 2009;126:603–604.

Bachas C, Schuurhuis GJ, Hollink IH, et al. High-frequency type I/II mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: Implications for personalized medicine. Blood. 2010;116:2752–2758. PubMed

Bachas C, Schuurhuis GJ, Reinhardt D, et al. Clinical relevance of molecular aberrations in paediatric acute myeloid leukaemia at first relapse. Br J Haematol. 2014;166:902–910. PubMed

Creutzig U, Ritter J, Schellong G. Identification of two risk groups in childhood acute myelogenous leukemia after therapy intensification in study AML-BFM-83 as compared with study AML-BFM-78. AML-BFM Study Group. Blood. 1990;75:1932–1940. PubMed

Creutzig U, van den Heuvel-Eibrink MM, Gibson B, et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: Recommendations from an international expert panel. Blood. 2012;120:3187–3205. PubMed

Betts DR, Ammann RA, Hirt A, et al. The prognostic significance of cytogenetic aberrations in childhood acute myeloid leukaemia: A study of the Swiss Paediatric Oncology Group (SPOG) Eur J Haematol. 2007;78:468–476. PubMed

Schoch C, Haase D, Haferlach T, et al. Fifty-one patients with acute myeloid leukemia and translocation t(8;21)(q22;q22): An additional deletion in 9q is an adverse prognostic factor. Leukemia. 1996;10:1288–1295. PubMed

Gupta V, Minden MD, Yi QL, et al. Prognostic significance of trisomy 4 as the sole cytogenetic abnormality in acute myeloid leukemia. Leuk Res. 2003;27:983–991. PubMed

Nishii K, Usui E, Katayama N, et al. Characteristics of t(8;21) acute myeloid leukemia (AML) with additional chromosomal abnormality: Concomitant trisomy 4 may constitute a distinctive subtype of t(8;21) AML. Leukemia. 2003;17:731–737. PubMed

Shimada A, Taki T, Tabuchi K, et al. KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): A study of the Japanese Childhood AML Cooperative Study Group. Blood. 2006;107:1806–1809. PubMed

Boissel N, Leroy H, Brethon B, et al. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML) Leukemia. 2006;20:965–970. PubMed

Manara E, Bisio V, Masetti R, et al. Core-binding factor acute myeloid leukemia in pediatric patients enrolled in the AIEOP AML 2002/01 trial: Screening and prognostic impact of c-KIT mutations. Leukemia. 2014;28:1132–1134. PubMed

Goemans BF, Zwaan CM, Miller M, et al. Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. Leukemia. 2005;19:1536–1542. PubMed

Shih LY, Liang DC, Huang CF, et al. Cooperating mutations of receptor tyrosine kinases and Ras genes in childhood core-binding factor acute myeloid leukemia and a comparative analysis on paired diagnosis and relapse samples. Leukemia. 2008;22:303–307. PubMed

Pollard JA, Alonzo TA, Gerbing RB, et al. Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. Blood. 2010;115:2372–2379. PubMed PMC

Beghini A, Ripamonti CB, Cairoli R, et al. KIT activating mutations: Incidence in adult and pediatric acute myeloid leukemia, and identification of an internal tandem duplication. Haematologica. 2004;89:920–925. PubMed

Goemans BF, Zwaan CM, Cloos J, et al. FLT3 and KIT mutated pediatric acute myeloid leukemia (AML) samples are sensitive in vitro to the tyrosine kinase inhibitor SU11657. Leuk Res. 2010;34:1302–1307. PubMed

Visani G, Bernasconi P, Boni M, et al. The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia: Analysis of 848 patients. Leukemia. 2001;15:903–909. PubMed

Byrd JC, Dodge RK, Carroll A, et al. Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol. 1999;17:3767–3775. PubMed

Bloomfield CD, Lawrence D, Byrd JC, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res. 1998;58:4173–4179. PubMed

Tsukimoto I, Tawa A, Horibe K, et al. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: The AML99 trial from the Japanese Childhood AML Cooperative Study Group. J Clin Oncol. 2009;27:4007–4013. PubMed

Lie SO, Abrahamsson J, Clausen N, et al. Treatment stratification based on initial in vivo response in acute myeloid leukaemia in children without Down's syndrome: Results of NOPHO-AML trials. Br J Haematol. 2003;122:217–225. PubMed

Klein K, Kaspers GJL. A review of liposomal daunorubicin in the treatment of acute leukemia. Oncol Hematol Rev. 2013;9:142–148.

Bishop JF, Lowenthal RM, Joshua D, et al. Etoposide in acute nonlymphocytic leukemia: Australian Leukemia Study Group. Blood. 1990;75:27–32. PubMed

Optimized cytogenetic risk-group stratification of KMT2A-rearranged pediatric acute myeloid leukemia

Prognostic impact of t(16;21)(p11;q22) and t(16;21)(q24;q22) in pediatric AML: a retrospective study by the I-BFM Study Group